JAZZ - Jazz Pharmaceuticals EPS beats by $0.89 beats on revenue

Jazz Pharmaceuticals (NASDAQ:JAZZ): Q3 Non-GAAP EPS of $4.20 beats by $0.89; GAAP EPS of -$0.86 beats by $1.39. Revenue of $838.12M (+39.5% Y/Y) beats by $6.07M. Press Release Net leverage ratio reduced by 0.5x to 4.4x1 in the five months following GW transaction close. Raising full year 2021 earnings guidance: Revenues $3,020 - $3,100M from $3,020 - $3,180M, Neuroscience $2,275 - $2,345M from $2,260 - $2,360M, Oncology $715 - $735M from $715 - $835M, Net loss per diluted share ($7.00) - ($5.40) from ($9.40) - ($6.70).

For further details see:

Jazz Pharmaceuticals EPS beats by $0.89, beats on revenue